Siponimod and Beta-Blocker Combination for Treating Autoimmune Disease
Summary
The USPTO published application US20260108490A1, a method-of-treatment patent covering siponimod in combination with a beta-blocker for treating autoimmune diseases, filed on December 22, 2025. The application names 11 inventors and classifies the invention under CPC categories including A61K (medicinal preparations) and A61P 37/00 (immunoregulating agents). Pharmaceutical companies developing autoimmune disease therapies should review freedom-to-operate positions regarding S1P receptor modulators combined with cardiovascular agents.
“The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 211 changes logged to date.
What changed
The USPTO published patent application US20260108490A1 for a method of treating autoimmune diseases using siponimod in patients who are additionally receiving a beta-blocker. The application, filed December 22, 2025, names 11 inventors and classifies the invention under therapeutic composition categories A61K and immunoregulating category A61P 37/00.
Pharmaceutical and biotech companies engaged in autoimmune disease drug development should assess potential freedom-to-operate implications arising from this patent filing, particularly regarding S1P receptor modulator and cardiovascular drug combination approaches. Researchers investigating siponimod combination therapies and competitive programs in the autoimmune space should factor this IP publication into their development and patent strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER
Application US20260108490A1 Kind: A1 Apr 23, 2026
Inventors
Vassilios Aslanis, Shibadas Biswal, Alan John Camm, Pierre Jordaan, Eric Legangneux, Parasar Pal, Atul Keshav Pawar, Florine Polus, Alexandros Sagkriotis, Kasra Shakeri-Nejad, Uday Kiran Veldandi
Abstract
The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
CPC Classifications
A61K 31/397 A61K 9/2018 A61K 31/138 A61K 45/06 A61P 37/00
Filing Date
2025-12-22
Application No.
19428890
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.